Ask Congress to Vote NO on Legislation Restricting Herbal and Homeopathic Remedies

0 have signed. Let’s get to 1,000!


The citizens of the United States of America request that Congress stop attempting to legislate away individual freedom with regards to healthcare.  Those of us that choose to utilize natural forms of medicine instead of pharmaceuticals have that right as sovereign entities.  Congress shall not impede upon this by forcing pharmaceutical drugs on citizens that wish to refrain.

As adults, we have the right to choose what enters our bodies, and do not want Congress to ban Kratom, or many other herbal remedies that we utilize within our private homes.  Please urge your colleagues to respect this.

Please vote no against any bill criminalizing natural remedies for pain, cancer, asthma, allergies, etc.  Some Americans have chosen alternative therapies, and we have a right to continue to do so.  Do not allow them to strip anymore freedom from our private homes.  We no longer wish to be forced into America's pharmaceutical epidemic.  Please sign the FDA's letter encouraging that Kratom remain a legal substance available to all Americans.

 

 

 You can also text " resist" 50409 and it will walk you through how to contact and send a letter to your reps

https://whoismyrepresentative.com/

https://docs.wixstatic.com/ugd/9ba5da_3ba321b19edf4c779fa59ba78582f470.pdf?mc_cid=d251e1cbc8&mc_eid=fa9b1d0aad

 

PRESERVE CONSUMER ACCESS AND SCIENTIFIC RESERCH INTO INNOVATIVE
TREATMENTS FOR OPIOID ADDICTION AND PREVENT DRUG ENFORCEMENT
AGENCY OVERREACH
Join Reps. Mark Pocan and Frank LoBiondo in Urging the Drug Enforcement Agency to Utilize All
Available Scientific Evidence When Making Final Scheduling Decisions on Kratom
Dear Colleague:
I invite you to join us in sending a bipartisan letter to the Drug Enforcement Agency to encourage them to employ
all the available scientific information on kratom before making any final decisions on the scheduling of this natural
product under the Controlled Substances Act (CSA).
Last year, the DEA attempted to expedite scheduling of kratom as a Schedule I substance without any public
comment or input. A group of 50 bipartisan Members of Congress urged them to halt the expedited process to
ensure that the public and scientists were able to provide comment and input before this significant decision was
made. Ultimately, the DEA heard Congress’ concerns and pulled the expedited schedule.
Now, the DEA has used the formal process to analyze whether kratom should be on listed under the Controlled
Substances Act (CSA). Kratom is not an opioid, it is a natural supplement made from the leaves of a tropical tree
native to Southeast Asia and a relative of the coffee plant. Kratom leaves are often brewed like a tea, or crushed and
mixed with water. In the U.S., kratom has been used as an herbal supplement by consumers for managing their
personal health and well-being. Numerous scientific studies, including studies funded by the NIH, have shown the
addiction potential for kratom is substantially lower than that of “narcotic-like opioids” and it does not produce the
deadly respiratory depressant effects that is the primary cause of opioid overdose deaths.
1 2
As our country continues to deal with the damage and pain the opioid crisis is causing our communities, it is
important to consider all scientific research that has been conducted on the use and safety of kratom. To date, the
FDA public health advisory of kratom encouraged the public to “conduct the research that will help us better
understand kratom’s risk and benefit profile.”
3 However, should the DEA schedule kratom through the CSA, it will
greatly reduce the public’s ability to conduct this important research. We remain concerned that any scheduling of
kratom would likely “create a substantial illicit market” where consumers would be put at significant safety risks, or
drive consumers to the dangerously addictive and potentially deadly use of opioids.
Please join us in this effort to ensure the DEA takes into all available scientific evidence regarding the safety and
efficacy of kratom. We need to continue to conduct research and find innovative treatments for individuals suffering
from opioid and other addictions—a significant public health threat. If you have questions or would like to sign on
to the letters, please contact Leslie Zelenko in Rep. Mark Pocan’s office at 202-225-2906 or Eric Arndt in Rep.
Frank LoBiondo’s office at 202-225-6572.
Sincerely,
Mark Pocan Frank A. LoBiondo

1 Kruegel AC and Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary
discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2017 Aug 19.
2 Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, Javitch JA, Sames D. Synthetic and
receptor signaling explorations of the mitragyna alkaloids: Mitragynine as an atypical molecular framework for
opioid receptor modulators. J Am Chem Soc. 2016 Jun 1;138(21):6754-64.
3 Federal Drug Administration. “Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA advisory about
deadly risks associated with kratom” November 14, 2017.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584970.htm
Member of Congress Member of Congress
The Honorable Robert Patterson
Administrator (Acting)
Drug Enforcement Administration
U.S. Department of Justice
8701 Morrissette Drive
Springfield, VA 22152
December X, 2017
Dear Acting Administrator Patterson:
Recent reports indicate the Federal Drug Administration (FDA) has sent over their Eight Factor Analysis
(8FA) of mitragynine and 7-Hydroxymitragynine, more commonly known as kratom. As you review the
analysis, we urge you to take all the available scientific information on kratom into consideration before
making any final decisions on the scheduling of kratom under the Controlled Substances Act (CSA).
As you are aware, the CSA sets specific and intentionally restrictive standards for scheduling of
substances in Schedule I, including conclusive scientific and legally defensible proof that the substance
has (1) a high abuse potential; and (2) there is a lack of accepted safety for use of the drug or other
substance under medical supervision.
Kratom is not an opioid, it is a natural supplement made from the leaves of a tropical tree native to
Southeast Asia and a relative of the coffee plant. Kratom leaves are often brewed like a tea, or crushed
and mixed with water. In the U.S., kratom has been used as an herbal supplement by consumers for
managing their personal health and well-being. Numerous scientific studies, including studies funded by
the NIH, have shown the addiction potential for kratom is substantially lower than that of “narcotic-like
opioids” and it does not produce the deadly respiratory depressant effects that is the primary cause of
opioid overdose deaths.
4 5
We additionally ask that you fully review the 8FA on kratom authored by a leading independent authority
on addiction and safety of substances, Jack E. Henningfield, that was submitted to the DEA in
conjunction with a previous review of kratom.6 The conclusions of Dr. Henningfield’s 8FA, that mirrored
the CSA requirements both the FDA and DEA should use in scheduling recommendations, document that
“placement of kratom in the CSA is not warranted from a public health perspective, and is likely to cause
public health problems that do not currently exist.”
Equally important, Dr. Henningfield’s research directly contradicts claims being made about deaths
allegedly caused by kratom; that kratom is dangerously addictive; and that kratom has the same opioidlike
effects in depressing the respiratory system. The fact that kratom may be mixed or blended with other
toxic doses of prescription drugs or other illegal substances is not an appropriate basis for scheduling

4 Kruegel AC and Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary
discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2017 Aug 19.
5 Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, Javitch JA, Sames D. Synthetic and
receptor signaling explorations of the mitragyna alkaloids: Mitragynine as an atypical molecular framework for
opioid receptor modulators. J Am Chem Soc. 2016 Jun 1;138(21):6754-64.
6 Pinney Associates (Henningfield JE and Fant RV, principal authors) (2016) Assessment of Kratom under the CSA
Eight Factors and Scheduling Recommendation. In Hogan Lovells US LLP Comment on FR Doc #2016-24659.
https://www.regulations.gov/document?D=DEA-2016-0015-23186 or http://www.pinneyassociates.com/our-work/
under the statute. The FDA and DEA have sufficient statutory authority to interdict such illegal
compounding, and we support the aggressive use of these powers to interdict those responsible for such
adulteration and contamination of kratom products.
As our country continues to deal with the damage and pain the opioid crisis is causing our communities, it
is important to consider all scientific research that has been conducted on the use and safety of kratom. To
date, the FDA public health advisory of kratom encouraged the public to “conduct the research that will
help us better understand kratom’s risk and benefit profile.”
7 However, should the DEA schedule kratom
through the CSA, it will greatly reduce the public’s ability to conduct this important research. We remain
concerned that any scheduling of kratom would likely “create a substantial illicit market” where
consumers would be put at significant safety risks, or drive consumers to the dangerously addictive and
potentially deadly use of opioids.
The DEA has a limited amount of resources, and we feel taxpayer dollars should be prioritized to prevent
the sale of illegal substances like heroin and fentanyl. These substances are causing the deaths of up to 90
Americans each day. Resources must be focused on preventing access to these most dangerous
substances. The Food and Drug Administration (FDA) has the authority to create a balanced regulatory
scheme for kratom, as a dietary supplement, to ensure consumer safety and quality.
Again, we strongly encourage the DEA to use all available scientific evidence on kratom when making a
final decision about whether to place the plant on the CSA list or not. We look forward to your timely
response.
Sincerely,

7 Federal Drug Administration. “Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA advisory about
deadly risks associated with kratom” November 14, 2017.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584970.htm



Today: Sarah is counting on you

Sarah Firebaugh needs your help with “Rand Paul: Ask Congress to Vote NO on Legislation Restricting Herbal and Homeopathic Remedies”. Join Sarah and 915 supporters today.